Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct;11(10):1988-1994.
doi: 10.21037/tlcr-22-634.

Lung function impairment in lung cancer screening: discordance between risk and screening outcomes when looking through a PRISm

Robert P Young  1 , Raewyn J Scott  1 , Greg D Gamble  1
Affiliations
Editorial

Lung function impairment in lung cancer screening: discordance between risk and screening outcomes when looking through a PRISm

Robert P Young et al. Transl Lung Cancer Res. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-634/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
LC characteristics and outcomes of screening in the ACRIN-NLST subgroup (n=18,463), after stratification by baseline spirometry into normal and impaired lung function (PRISm and COPD). While the adjusted LC prevalence (risk) increases in a linear relationship (black line), there is a significant downward inflection for PRISm (P<0.05 relative to Normal), where there are more advanced LCs (significantly less stage 1–2, green line), less adenocarcinomas (blue dotted line), less surgery (brown dotted line) and the greatest LC lethality (grey dashed line). This corresponds to the lowest (but non-significant) relative reduction in LC deaths favouring the CT arm (P>0.05). LC, lung cancer; CT, computed tomography; BAC, bronchioloalveolar carcinoma; ACRIN-NLST, American College of Radiology Imaging Network-National Lung Screening Trial; PRISm, preserved ratio impaired spirometry; COPD, chronic obstructive pulmonary disease.
See this image and copyright information in PMC

Comment on

References

    1. National Lung Screening Trial Research Team , Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed
    1. Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2020;146:1503-13. 10.1002/ijc.32486 - DOI - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020;382:503-13. 10.1056/NEJMoa1911793 - DOI - PubMed
    1. Tammemägi MC. Selecting lung cancer screenees using risk prediction models-where do we go from here. Transl Lung Cancer Res 2018;7:243-53. 10.21037/tlcr.2018.06.03 - DOI - PMC - PubMed
    1. Atwater T, Massion PP. Biomarkers of risk to develop lung cancer in the new screening era. Ann Transl Med 2016;4:158. 10.21037/atm.2016.03.46 - DOI - PMC - PubMed